| Name | Title | Contact Details |
|---|---|---|
Michael Olszowy |
Chief Technology Officer | Profile |
Cardeas BPU™ (Biosignal Processing Unit) is a biocompatible semiconductor capable of translating real-time streams of multiomics signals to digital information
Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients` lives. Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug`s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana`s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today`s cancer treatments.
Ziemer USA INC is a Wood River, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Potenza Therapeutics is a biotechnology company focused on building a diverse portfolio of oncology programs that utilize the body`s own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms. Our programs are built upon novel biological insights into the tumor microenvironment and mechanisms by which cancer cells evade detection and destruction by the immune system. Potenza Therapeutics was founded in 2014 and is located in Cambridge, MA.
Verax Biomedical Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.